Olanzapine for psychosis in patients with Parkinson's disease with and without dementia

J Neuropsychiatry Clin Neurosci. Summer 1999;11(3):392-4. doi: 10.1176/jnp.11.3.392.

Abstract

Twenty-one patients with Parkinson's disease and psychosis were included in an open-label 8-week trial of olanzapine. Eight subjects had dementia. Six subjects (29%) discontinued treatment prematurely because of drowsiness. Delusions and hallucinations improved significantly, and 80% were rated as much or very much improved. There was no worsening of parkinsonism or cognition.

MeSH terms

  • Aged
  • Antipsychotic Agents / therapeutic use*
  • Benzodiazepines
  • Dementia / complications*
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Male
  • Neuropsychological Tests
  • Olanzapine
  • Parkinson Disease / complications*
  • Pirenzepine / analogs & derivatives*
  • Pirenzepine / therapeutic use
  • Prospective Studies
  • Psychotic Disorders / complications*
  • Psychotic Disorders / drug therapy*
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antipsychotic Agents
  • Benzodiazepines
  • Pirenzepine
  • Olanzapine